Table 1.
Clinical data
| Pts | Sex/age (year) | Sites of involvement | Stage | Treatment | Outcome |
|---|---|---|---|---|---|
| 1 | F/61 | Spleen, bone marrow and blood | 4 | Splenectomy. Rituximab and interferonα; later treated in analogue to the 3rd Nordic MCL-protocola, with partial response, thereafter rituximab maintenance therapy every 3 months | CR |
| 2 | M/61 | Lymph nodes, bone marrow and duodenum | 4 | 6 × Maxi-CHOPb, thereafter rituximab maintenance therapy every 3 months | CR |
| 3 | M/82 | Lymph nodes, bone marrow and stomach | 4 | Died before the start of treatment | Died with disease |
| 4 | F/80 | Rectum, bone marrow | 4 | Chlorambucil | PR, died of sepsis |
| 5 | F/65 | Lymph nodes | 4 | According to the 3rd Nordic MCL protocola | CR |
| 6 | M/84 | Bone marrow | 4 | None | Died with disease |
| 7 | M/85 | Colon, bone marrow | 4 | Reduced CHOP-treatment | Died with disease |
athird Nordic MCL-protocol: alternating cytarabine 3 g/m2 every 12 h for a total of four doses (2 g/m2 for patients over 60) + rituximab 375 mg/m2 and maxi-CHOPb + rituximab; three courses of each, followed by high-dose therapy with autologous stem cell support (karmustin 300 mg/m2 day 1, etoposide 300 mg/m2 days 1–4, cytarabine 400 mg/m2 days 1–4 and melfalan 140 mg/m2 day 5)
bMaxi-CHOP: (cyclophosphamide 1,200 mg/m2, doxorubicin 75 mg/m2, vincristin 2 mg/m2 (all day 1) prednisolon 50 mg tablet × 2 per day, days 1–5) + rituximab; totally six courses